Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide for cognitive impairment associated with cerebral amyloid angiopathy in type 2 diabetes and overweight
ChiCTR2600129902Phase 4Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Aug 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label trial of tirzepatide in type 2 diabetes mellitus (T2DM), obesity, Overweight and 2 more (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Change in MMSE score from baseline after 48 weeks of treatment. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)obesityOverweightcerebral amyloid angiopathy (CAA)confusion
Beyond the preview
Go deeper on ChiCTR2600129902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600129902.